Tue-15-10-2013, 13:37 PM
New pre-filled pen type self-injectable Methotrexate should be available early 2014
For more information on the use of Methotrexate see: Methotrexate
Quote:
Antares Pharma today announced the approval of OTREXUP (methotrexate) injection by the U.S. Food and Drug Administration (FDA). OTREXUP is the first FDA approved subcutaneous (SC) methotrexate (MTX) for once weekly self-administration with an easy to use, single dose, disposable auto injector.
“This new delivery system for methotrexate provides a welcome option for physicians and their patients to continue effective use of methotrexate. OTREXUP can be used when a response is inadequate or there are tolerability issues with oral methotrexate, before adding or switching to costlier therapies,” said Dr. Michael Schiff, Clinical Professor of Medicine in the Rheumatology Division at the University Of Colorado School Of Medicine in Denver. “The availability of an easy and safe way to administer subcutaneous methotrexate may overcome some of the current barriers to parenteral administration which could enable more patients to realize the possibility of continued disease control and therefore benefit from subcutaneous methotrexate.”
Otrexup is a single dose auto injector for once weekly subcutaneous use only. Administer Otrexup in the abdomen or the thigh. Otrexup is only available in doses between 10 to 25 mg in 5 mg increments.
Source: NO LINKS ALLOWED
For more information on the use of Methotrexate see: Methotrexate